Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsProvidence Botulinum Toxin Coverage | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentProvidence Health PlanPolicy ORPTCNEU029.0826

    Neuromuscular Drugs: Botulinum Toxin

    Customize your policy alerts

    Sign up for Providence Health Plan Policy ORPTCNEU029.0826 alerts

    Get alerted when Policy ORPTCNEU029.0826 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of botulinum toxin products for Providence Health Plan commercial and Medicaid members, including Oregon Health Plan members. Coverage is limited to FDA-approved or otherwise medically accepted product-specific indications, subject to age criteria, benefit exclusions, and Oregon Medicaid requirements.

    Policy Summary
    PayerProvidence Health Plan
    PolicyNeuromuscular Drugs: Botulinum Toxin
    Policy CodePolicy ORPTCNEU029.0826
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for initial therapy and reauthorization; approvals are issued for one year.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5Covered botulinum toxin products
    6Listed botulinum toxin drug codes
    1 yearAuthorization duration
    ExcludedCosmetic use
    OregonMedicaid scope
    2–12+ yearsSelected age criteria

    Coverage Criteria

    Product-specific medically necessary indications

    Botulinum toxin therapy may be considered medically necessary when the requested product is used for one of the following product-specific indications and applicable age criteria are met.

    Covered product-specific indications

    • OnabotulinumtoxinA (Botox): Chronic migraine headaches in adults; upper or lower limb spasticity in patients at least 2 years of age; cervical dystonia in adults; strabismus or blepharospasm associated with dystonia in patients at least 12 years of age; axillary or palmar hyperhidrosis in adults; overactive bladder in adults; urinary incontinence in patients at least 5 years of age; excessive salivation due to advanced Parkinson's disease; hemifacial spasm; chronic anal fissure in adults; spastic dysphonia/laryngeal dystonia in adults; achalasia; oromandibular dystonia in adults; or focal hand dystonia in adults.
    • AbobotulinumtoxinA (Dysport): Spasticity in patients 2 years of age and older; cervical dystonia in adults; or blepharospasm in adults.
    Policy Summary
    PayerProvidence Health Plan
    PolicyNeuromuscular Drugs: Botulinum Toxin
    Policy CodePolicy ORPTCNEU029.0826
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for initial therapy and reauthorization; approvals are issued for one year.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Scope TablesAuthorization, Documentation, and Denial RisksClinical BackgroundPolicy DefinitionsInitial TherapyContinuation and Reauthorization
    IncobotulinumtoxinA (Xeomin):
    Chronic sialorrhea in patients 2 years of age and older; upper limb spasticity in patients at least 2 years of age; cervical dystonia in adults; or blepharospasm in adults.
  1. RimabotulinumtoxinB (Myobloc): Cervical dystonia in adults or chronic sialorrhea in adult patients.
  2. DaxibotulinumtoxinA-lanm (Daxxify): Cervical dystonia in adults.
  3. Medicaid and EPSDT coverage requirements

    For Oregon Medicaid and Oregon Health Plan members, all of the following requirements apply.

    Oregon Medicaid requirements

    • The condition is designated as a covered line item on the Oregon Health Services Commission Prioritized List, unless EPSDT requirements apply.
    • Applicable Oregon Administrative Rules and indication-specific criteria are met.
    • For Medicaid-enrolled children and adolescents through age 20, the requested service is medically necessary and medically appropriate under the EPSDT benefit.

    General medical-necessity requirements

    Botulinum toxin therapy may be considered medically necessary when all of the following requirements are met.

    Medical necessity requirements

    • The billed botulinum toxin medication HCPCS code corresponds to a diagnosis code listed for that medication in the medical-necessity diagnosis table.
    • The member meets the age restriction associated with the medication and diagnosis-code combination.Adults only, at least 2 years, or at least 5 years as specified

      Some diagnosis-code combinations have no age restriction or are marked N/A.

    • The service is billed using the applicable CPT or HCPCS code and the instructions in the Billing Guidelines Appendix.

      Code inclusion does not by itself guarantee reimbursement or coverage.

    Non-covered and not medically necessary conditions

    Coverage is not available when any of the following applies.

    Non-covered or not medically necessary use

    • Botulinum toxin is used cosmetically to treat glabellar lines, fine wrinkles on the face, or platysma bands associated with platysma muscle activity.
    • The requested product is prabotulinumtoxinA (Jeuveau) for glabellar lines and/or fine facial wrinkles.
    • The diagnosis is glabellar lines coded L98.8.
    • The billed diagnosis code is not listed for the medication in the medical-necessity diagnosis table.

    Age-specific scope criteria

    The member must satisfy the age qualifier assigned to the applicable diagnosis and botulinum toxin code combination.

    Age eligibility: The applicable diagnosis and botulinum toxin code combination permits coverage for the member's age.Adults only, at least 2 years, at least 5 years, or at least 12 years, depending on the listed combination

    Some combinations have no age restriction or are marked N/A.

    Scope code and diagnosis combinations with age restrictions

    Coverage scope includes the listed botulinum toxin HCPCS codes only when paired with an applicable diagnosis code and age qualifier.

    Listed code and diagnosis combinations

    • J0585, J0586, J0587, or J0588 is paired with a diagnosis code listed in the policy scope.
    • The member meets the age restriction shown for the applicable code and diagnosis combination.Adults only, at least 2 years, or at least 12 years as specified

    Cosmetic use is not covered when botulinum toxin is used to treat glabellar lines, fine wrinkles on the face, or platysma bands associated with platysma muscle activity.

    PrabotulinumtoxinA (Jeuveau) is not covered under this policy because its FDA-approved use is limited to glabellar lines and/or fine wrinkles on the face.

    Glabellar lines reported with diagnosis code L98.8 are excluded from coverage.

    A billed diagnosis code that is not listed in the policy’s medical-necessity diagnosis table is considered not medically necessary.

    An unlisted procedure code submitted for a non-covered service addressed by this policy will be denied as not covered. Unlisted codes are reviewed at the claim level for medical necessity, correct coding, and pricing; prior authorization is recommended before submitting an unlisted code for a potentially covered service.

    Coding and Scope Tables

    Covered CPT procedure codesCPTCovered
    31513Laryngoscopy, indirect; with vocal cord injection
    31570Laryngoscopy, direct, with injection into vocal cord(s), therapeutic
    31571Laryngoscopy, direct, with injection into vocal cord(s), therapeutic; with operating microscope or telescope
    31573Laryngoscopy, flexible; with therapeutic injection(s), unilateral
    43192Esophagoscopy, rigid, transoral; with directed submucosal injection(s), any substance
    43201Esophagoscopy, flexible, transoral; with directed submucosal injection(s), any substance
    43236Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any substance
    46505Chemodenervation of internal anal sphincter
    52287Cystourethroscopy, with injection(s) for chemodenervation of the bladder
    64611Chemodenervation of parotid and submandibular salivary glands, bilateral
    1–10 of 23
    1/3
    Botulinum toxin drug HCPCS codesHCPCSCovered
    J0585Injection, onabotulinumtoxina, 1 unit
    J0586Injection, abobotulinumtoxina, 5 units
    J0587Injection, rimabotulinumtoxinb, 100 units
    J0588Injection, incobotulinumtoxin a, 1 unit
    J0589Injection, daxibotulinumtoxina-lanm, 1 unit
    J3590Injection, prabotulinumtoxin a
    Additional and unlisted procedure codesCPT
    S2340Chemodenervation of abductor muscle(s) of vocal cord
    S2341Chemodenervation of adductor muscle(s) of vocal cord
    31599Unlisted procedure, larynx
    43499Unlisted procedure, esophagus
    64999Unlisted procedure, nervous system
    Non-covered diagnosis codesICD-10Not Covered
    L98.8Glabellar lines
    Medical-necessity diagnosis codes and age restrictionsICD-10Covered
    F64.0Listed diagnosis for J0585, J0586, and J0587
    F64.1Listed diagnosis for J0585, J0586, and J0587
    F64.8Listed diagnosis for J0585, J0586, and J0587
    F64.9Listed diagnosis for J0585, J0586, and J0587
    G43.70Listed diagnosis for J0585, J0586, and J0587
    G43.701Listed diagnosis for J0585
    G43.709Listed diagnosis for J0585
    G43.71Listed diagnosis for J0585
    G43.711Listed diagnosis for J0585
    G43.719Listed diagnosis for J0585
    1–10 of 27
    1/3
    Additional medical-necessity diagnosis codesICD-10Covered
    K11.7Listed diagnosis in the medical-necessity table for botulinum toxin therapy
    G20.A1Listed diagnosis in the medical-necessity table
    G20.A2Listed diagnosis in the medical-necessity table
    G20.B1Listed diagnosis in the medical-necessity table
    G20.B2Listed diagnosis in the medical-necessity table
    G20.CListed diagnosis in the medical-necessity table
    G21.0Listed diagnosis in the medical-necessity table
    G21.1Listed diagnosis in the medical-necessity table
    G21.11Listed diagnosis in the medical-necessity table
    G21.19Listed diagnosis in the medical-necessity table
    1–10 of 19
    1/2
    Botulinum toxin HCPCS codesHCPCS
    J0585HCPCS code listed in the botulinum toxin scope matrix.
    J0586HCPCS code listed in the botulinum toxin scope matrix.
    Diagnosis codes appearing in the scope matrixICD-10
    G20.A1Diagnosis code listed in the scope matrix.
    G20.A2Diagnosis code listed in the scope matrix.
    G20.B1Diagnosis code listed in the scope matrix.
    G20.B2Diagnosis code listed in the scope matrix.
    G20.CDiagnosis code listed in the scope matrix.
    G21.0Diagnosis code listed in the scope matrix.
    G21.1Diagnosis code listed in the scope matrix.
    G21.11Diagnosis code listed in the scope matrix.
    G21.19Diagnosis code listed in the scope matrix.
    G21.2Diagnosis code listed in the scope matrix.
    1–10 of 26
    1/3
    Botulinum toxin drug codesHCPCS
    J0585
    J0586
    J0588
    J0587
    Scope diagnosis and indication codesICD-10
    G20.B2
    G20.C
    G21.0
    G21.1
    G21.11
    G21.19
    G21.2
    G21.3
    G21.4
    G21.8
    1–10 of 24
    1/3
    Scope diagnosis and botulinum toxin HCPCS codesmixed
    J0585Listed in the scope table; associated diagnosis and age qualifiers vary by entry.
    J0586Listed in the scope table; associated diagnosis and age qualifiers vary by entry.
    J0587Listed in the scope table; associated diagnosis and age qualifiers vary by entry.
    J0588Listed in the scope table; associated diagnosis and age qualifiers vary by entry.
    G21.0Listed in the scope table.
    G21.1Listed in the scope table.
    G21.11Listed in the scope table.
    G21.19Listed in the scope table.
    G21.2Listed in the scope table.
    G21.3Listed in the scope table.
    1–10 of 29
    1/3
    Scope diagnosis codesICD-10Covered
    G21.11Listed in scope table; no diagnosis description shown.
    G21.19Listed in scope table; no diagnosis description shown.
    G21.2Listed in scope table; no diagnosis description shown.
    G21.3Listed in scope table; no diagnosis description shown.
    G21.4Listed in scope table; no diagnosis description shown.
    G21.8Listed in scope table; no diagnosis description shown.
    G21.9Listed in scope table; no diagnosis description shown.
    G51.31Listed in scope table; no diagnosis description shown.
    G51.32Listed in scope table; no diagnosis description shown.
    G51.33Listed in scope table; no diagnosis description shown.
    1–10 of 25
    1/3
    Scope botulinum toxin HCPCS codesHCPCSCovered
    J0585Listed in scope table; no drug description shown.
    J0586Listed in scope table; no drug description shown.
    J0587Listed in scope table; no drug description shown.
    J0588Listed in scope table; no drug description shown.
    Botulinum toxin HCPCS codesHCPCS
    J0585Botulinum toxin product code; age and diagnosis mappings shown in scope table
    J0586Botulinum toxin product code; age and diagnosis mappings shown in scope table
    J0587Botulinum toxin product code; age and diagnosis mappings shown in scope table
    J0588Botulinum toxin product code; age and diagnosis mappings shown in scope table
    Diagnosis codes in scope mappingsICD-10
    G21.3Diagnosis code listed in scope table
    G21.4Diagnosis code listed in scope table
    G21.8Diagnosis code listed in scope table
    G21.9Diagnosis code listed in scope table
    G51.31Diagnosis code listed in scope table
    G51.32Diagnosis code listed in scope table
    G51.33Diagnosis code listed in scope table
    G51.39Diagnosis code listed in scope table
    K60.1Diagnosis code listed in scope table
    J38.3Diagnosis code listed in scope table
    1–10 of 25
    1/3
    Botulinum toxin drug codes listed in scopeHCPCS
    J0585
    J0586
    J0587
    J0588
    Diagnosis codes listed in scopeICD-10
    G21.9
    G24.4
    G24.5
    G24.8
    G24.9
    G51.31
    G51.32
    G51.33
    G51.39
    H49.00
    1–10 of 24
    1/3
    Botulinum toxin HCPCS codesHCPCS
    J0585Listed in scope; no textual description provided
    J0586Listed in scope; no textual description provided
    J0587Listed in scope; no textual description provided
    J0588Listed in scope; no textual description provided
    Associated diagnosis codesICD-10
    G24.4Listed in scope; no textual description provided
    G24.5Listed in scope; no textual description provided
    G24.8Listed in scope; no textual description provided
    G24.9Listed in scope; no textual description provided
    G51.32Listed in scope; no textual description provided
    G51.33Listed in scope; no textual description provided
    G51.39Listed in scope; no textual description provided
    H49.00Listed in scope; no textual description provided
    H49.01Listed in scope; no textual description provided
    H49.02Listed in scope; no textual description provided
    1–10 of 24
    1/3
    Scope diagnosis and HCPCS code listingsmixed
    J0585
    J0586
    J0587
    J0588
    J38.3
    J38.5
    K22.0
    G24.4
    G24.5
    G24.8
    1–10 of 26
    1/3
    Botulinum toxin HCPCS codesHCPCSCovered
    J0585Botulinum toxin drug code listed in scope
    J0586Botulinum toxin drug code listed in scope
    J0587Botulinum toxin drug code listed in scope
    J0588Botulinum toxin drug code listed in scope
    Diagnosis codes listed in botulinum toxin scopeICD-10Covered
    G24.4Diagnosis code listed in scope
    G24.5Diagnosis code listed in scope
    G24.8Diagnosis code listed in scope
    G24.9Diagnosis code listed in scope
    K11.7Diagnosis code listed in scope
    H49.00Diagnosis code listed in scope
    H49.01Diagnosis code listed in scope
    H49.02Diagnosis code listed in scope
    H49.03Diagnosis code listed in scope
    H49.10Diagnosis code listed in scope
    1–10 of 21
    1/3
    Botulinum toxin HCPCS codesHCPCS
    J0585
    J0586
    J0587
    J0588
    G24 diagnosis codesICD-10
    G24.4
    G24.5
    G24.8
    G24.9
    K diagnosis codesICD-10
    K11.7
    K22.0
    H49 diagnosis codesICD-10
    H49.00
    H49.01
    H49.02
    H49.03
    H49.10
    H49.11
    H49.12
    H49.13
    H49.20
    H49.21
    1–10 of 14
    1/2
    Botulinum toxin HCPCS codesHCPCS
    J0585
    J0586
    J0587
    J0588
    Dystonia diagnosis codesICD-10
    G24.4
    G24.5
    G24.8
    G24.9
    Sialorrhea diagnosis codeICD-10
    K11.7
    H49 ophthalmoplegia/strabismus-related diagnosis codesICD-10
    H49.00
    H49.01
    H49.02
    H49.03
    H49.10
    H49.11
    H49.12
    H49.13
    H49.20
    H49.21
    1–10 of 14
    1/2
    Medication HCPCSHCPCS
    J0585Medication HCPCS
    J0586Medication HCPCS
    J0587Medication HCPCS
    J0588Medication HCPCS
    K11.7Medication HCPCS
    ICD-10 Diagnosis CodesICD-10
    G24.5ICD-10 Diagnosis Codes
    G24.8ICD-10 Diagnosis Codes
    G24.9ICD-10 Diagnosis Codes
    H49.00ICD-10 Diagnosis Codes
    H49.01ICD-10 Diagnosis Codes
    H49.02ICD-10 Diagnosis Codes
    H49.03ICD-10 Diagnosis Codes
    H49.10ICD-10 Diagnosis Codes
    H49.11ICD-10 Diagnosis Codes
    H49.12ICD-10 Diagnosis Codes
    1–10 of 109
    1/11
    Age requirement
    Diagnosis codeM62.838
    Minimum ageAt least two years of age
    Applicable productsJ0585 or J0586
    Age requirement
    Diagnosis groupSelected urinary-incontinence diagnoses billed with J0585
    Minimum ageAt least five years of age
    Listed diagnosesR39.81, R32, N39.3, N39.41, N39.42, N39.43, N39.44, N39.45, N39.46, N39.490, N39.491, N39.492, and N39.498
    Adult-only indications
    Age qualifierAdults only
    Applicable diagnosesG43.701, G43.709, G43.71, G43.711, and G43.719
    Applicable productJ0585
    Adult-only restrictions
    Age qualifierAdults only
    ScopeSelected diagnosis and botulinum toxin code combinations
    RestrictionThe member must meet the adults-only requirement shown for the applicable mapping
    Age requirement
    Diagnosis codeK11.7
    Minimum ageAt least two years of age
    ScopeSelected botulinum toxin code combinations
    Adult age qualifier
    Age qualifierAdults only
    ScopeDiagnosis and botulinum toxin HCPCS code combinations in the scope table
    ApplicationApplies where the listed mapping specifies adults only
    Pediatric age qualifier
    Pediatric qualifierAt least two years of age
    ScopeDiagnosis and botulinum toxin HCPCS code combinations in the scope table
    ApplicationApplies where the listed mapping specifies the minimum age
    Minimum age
    Diagnosis codeK11.7
    Minimum ageAt least two years of age
    ScopeCertain K11.7 entries in the scope table
    Adult age restriction
    Age qualifierAdults only
    ScopeSpecified diagnosis-code entries in the scope table
    ApplicationCoverage is restricted to members meeting the adults-only designation
    Minimum age
    Diagnosis codeK11.7
    Minimum ageAt least two years of age
    ScopeSelected K11.7 mappings
    Adult-only mappings
    Age qualifierAdults only
    ScopeSelected diagnosis and botulinum toxin code mappings
    ApplicationCoverage is restricted to members meeting the adults-only designation
    Age requirement
    Diagnosis codesH49.12 and H49.13
    Minimum ageAt least 12 years of age
    ScopeSelected H49.12/H49.13 mappings
    Age requirement
    Diagnosis codeK11.7
    Minimum ageAt least two years of age
    ScopeSelected botulinum toxin scope entries
    Adult-only indications
    Age qualifierAdults only
    ScopeSelected diagnosis and botulinum toxin code combinations
    ApplicationCoverage is restricted to members meeting the adults-only designation
    Age requirement
    Diagnosis groupH49 and related indication entries
    Minimum ageAt least 12 years of age
    ScopeSelected H49 mappings in the scope table
    Age requirement
    Diagnosis codeK11.7
    Minimum ageAt least two years of age
    ScopeSelected K11.7 scope entries
    Age requirement
    ScopeSpecified ophthalmic and neuromuscular entries
    Minimum ageAt least 12 years of age
    ApplicationThe requirement applies where the listed scope mapping specifies this age threshold
    Adult-only scope entries
    Age qualifierAdults only
    ScopeSelected diagnosis and botulinum toxin code combinations
    ApplicationCoverage is restricted to members meeting the adults-only designation
    Eligibility
    Eligibility qualifierAdults only
    ScopeSelected diagnosis and HCPCS code combinations
    ApplicationThe member must meet the adults-only designation shown in the scope listing
    Eligibility
    Minimum ageAt least two years of age
    ScopeSelected diagnosis and HCPCS code combinations
    ApplicationThe member must meet the minimum age shown in the scope listing
    Eligibility
    Minimum ageAt least 12 years of age
    ScopeSelected diagnosis and HCPCS code combinations
    ApplicationThe member must meet the minimum age shown in the scope listing
    Eligibility designation
    Eligibility designationN/A
    MeaningNo age or coverage qualifier is specified for the listed combination
    ScopeSelected diagnosis and HCPCS code combinations
    Age restrictions
    Adult-only combinationsAdults only
    Pediatric combinationsAt least two years of age
    Older pediatric combinationsAt least 12 years of age
    Adult age restriction
    Age qualifierAdults only
    ScopeSelected G24, K11.7, and H49 diagnosis combinations
    ApplicationCoverage is restricted where the listed combination specifies adults only
    Age restriction
    Minimum ageAt least two years of age
    ScopeSelected botulinum toxin and diagnosis combinations
    ApplicationThe member must meet the minimum age shown for the applicable combination
    Age restriction
    Minimum ageAt least 12 years of age
    ScopeSelected botulinum toxin and diagnosis combinations
    ApplicationThe member must meet the minimum age shown for the applicable combination
    Age applicability
    Age applicabilityN/A
    MeaningNo age qualifier is specified for the listed combination
    ScopeSelected botulinum toxin and diagnosis combinations
    Age restriction
    Minimum ageAt least two years of age
    ScopeSelected dystonia, sialorrhea, and related diagnosis combinations
    ApplicationThe member must meet the minimum age shown for the applicable combination
    Age restriction
    Minimum ageAt least 12 years of age
    ScopeSelected H49 diagnosis combinations
    ApplicationThe member must meet the minimum age shown for the applicable combination
    Adult age restriction
    Age qualifierAdults only
    ScopeSelected medication HCPCS and diagnosis-code combinations
    ApplicationCoverage is restricted where the listed combination specifies adults only
    Age restriction
    Minimum ageAt least two years of age
    ScopeSelected medication HCPCS and diagnosis-code combinations
    ApplicationThe member must meet the minimum age shown for the applicable combination
    Age restriction
    Minimum ageAt least 12 years of age
    ScopeSelected medication HCPCS and diagnosis-code combinations
    ApplicationThe member must meet the minimum age shown for the applicable combination

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Annual Authorization Period

    Initial authorization and reauthorization are approved for one year. Submit a new authorization request before the current authorization expires when continued treatment is needed.

    Prior Authorization

    Prior Authorization for Unlisted Codes

    All unlisted codes are reviewed at the claim level for medical necessity, correct coding, and pricing. Prior authorization is recommended before submitting an unlisted code for a potentially covered service to avoid post-service denial.

    • An unlisted code submitted for a non-covered service addressed by this policy will be denied as not covered.

    Unsupported block type: documentation

    Documentation Required

    Off-Label Supporting Documentation

    For a non-FDA-approved indication, document that the proposed use is listed in AHFS, DrugDex, or NCCN and provide the prescriber's medical rationale, formulary alternatives, and available published evidence-based research. The plan will determine whether the use is experimental or investigational.

    Billing Rule

    Billing and Authorization Documentation

    Submit complete authorization and billing documentation, including the applicable product, indication, diagnosis code, and clinical rationale. Code submissions remain subject to provider contract terms, member benefits, utilization audit, NCCI procedure-to-procedure edits, and CMS medically unlikely edits.

    • The code list may not be all-inclusive; inclusion or omission does not guarantee coverage or reimbursement.
    • Review the applicable Company Medical Policy, Reimbursement Policy, Pharmacy Policy, and Provider Information resources.
    Denial Risk

    Cosmetic Indications Excluded

    Cosmetic use of botulinum toxin is excluded from coverage.

    • Glabellar lines and fine facial wrinkles are not covered.
    • Platysma bands associated with platysma muscle activity are not covered.
    • PrabotulinumtoxinA (Jeuveau) is not covered because its FDA-approved indication is limited to glabellar lines and fine facial wrinkles.
    Prior Authorization

    Recently Approved Indications

    Requests for indications approved by the FDA within the previous six months may not yet have been reviewed by the health plan for safety, effectiveness, or inclusion in this policy. These requests require separate review under the New Drug and/or Indication Awaiting P&T Review process.

    • Use Prior Authorization Request ORPTCOPS047 for the separate review.
    Documentation Required

    Off-Label Use Requires Review

    Off-label requests are not automatically covered. The proposed indication must be supported by an accepted drug compendium and evaluated using the prescriber's rationale, available evidence, alternatives, and the treatment's experimental or investigational status.

    • Acceptable compendia include AHFS, DrugDex, and NCCN.
    • Coverage decisions are individualized determinations of medical necessity and experimental or investigational character.
    Prior Authorization

    Oregon Medicaid Coverage Restrictions

    For Oregon Medicaid/Oregon Health Plan members, use the OHP Prioritized List and applicable Oregon Administrative Rules as the primary coverage resources. Coverage is generally limited to conditions assigned a covered line-item number when the applicable indication-specific criteria are met.

    • EPSDT provides comprehensive and preventive coverage for Medicaid members through age 20; medically necessary and medically appropriate services for children and adolescents may be covered under the EPSDT standard.
    • Policy criteria may be applied when no applicable OAR or Prioritized List criteria exist.
    Denial Risk

    Non-Covered Service or Unlisted Diagnosis

    A service submitted with a non-covered indication or unlisted diagnosis is at risk for denial. Confirm coverage and the required diagnosis before treatment and claim submission.

    • An unlisted code for a non-covered service will be denied as not covered.
    • An unlisted code for a potentially covered service should be submitted with prior authorization to reduce post-service denial risk.
    Denial Risk

    Excluded or Unlisted Diagnosis

    Glabellar lines (ICD-10 L98.8) are excluded from coverage. A diagnosis code not listed in the policy's medically necessary diagnosis-code table may be considered not medically necessary.

    • Verify that the diagnosis code is listed for the specific botulinum toxin product before billing.
    Documentation Required

    Verify Age Restrictions

    Apply the age requirements in the product and indication scope table before requesting authorization or billing. Age restrictions vary by product and indication.

    • Spasticity: at least two years of age for applicable products.
    • Urinary incontinence: at least five years of age for onabotulinumtoxinA.
    • Strabismus and blepharospasm associated with dystonia: at least 12 years of age for onabotulinumtoxinA.
    • Several indications, including chronic migraine, cervical dystonia, hyperhidrosis, overactive bladder, and selected dystonias, are limited to adults.
    Denial Risk

    Age Requirement Not Met

    If the member does not meet the minimum age requirement for the requested product and indication, coverage may be restricted and the claim may be denied.

    • Confirm the member's age on the date of treatment and match it to the applicable product-specific requirement.
    • Do not assume that an indication covered for adults is covered for pediatric members.

    Clinical Background

    Botulinum toxins are type A or type B neurotoxins that produce a presynaptic neuromuscular blockade by preventing acetylcholine release. This causes localized chemical denervation and temporary muscle paresis or paralysis. Botulinum toxin products are pharmacologically and clinically distinct and are not interchangeable, so approved and covered indications differ by product. The safety and efficacy of long-term use are unknown.

    Policy Definitions

    Definitions
    TermMedically accepted indication
    DefinitionAn indication approved by the FDA or generally recognized as efficacious by certain drug compendia references
    Example referenceMicromedex
    Definitions
    TermOff-label indication
    DefinitionA non-FDA-approved indication listed in AHFS, DrugDex, or NCCN
    Review factorsMedical rationale, formulary alternatives, published evidence, and whether the use is experimental or investigational
    Definitions
    TermUnlisted procedure code
    ReviewReviewed at the claim level
    Review criteriaMedical necessity, correct coding, and pricing
    Definitions
    NCCI editsNational Correct Coding Initiative procedure-to-procedure bundling edits
    MUEsCMS medically unlikely edits, including daily maximum edits
    Policy relationshipThese edits may apply independently of this policy
    Definitions
    TermNeuromuscular drugs botulinum toxin
    ScopeNeuromuscular botulinum toxin services
    Associated informationDiagnosis-code combinations represented in the policy scope matrix

    Initial Therapy

    Initial product-specific therapy criteria

    Initial therapy may be considered medically necessary when all of the following requirements are met.

    Initial product-specific therapy

    • Covered indication: The selected botulinum toxin product is used for one of its listed covered product-specific indications.
    • Age requirement: The applicable patient age requirement for the selected product and indication is met.
    • Non-cosmetic use: The request is not for a cosmetic indication excluded by this policy, including glabellar lines, fine facial wrinkles, or platysma bands.

      PrabotulinumtoxinA (Jeuveau) is not covered for its FDA-approved cosmetic indications.

    Continuation and Reauthorization

    One-year reauthorization criteria

    Reauthorization is approved for one year when all of the following requirements are met.

    One-year reauthorization

    • The requested therapy continues to meet the applicable product-specific medically accepted indication and benefit requirements.
    • The applicable medical-necessity, diagnosis-code, billing, and age requirements continue to be satisfied.